西班牙化学及制药公司基立福（Grifols）近日与中国企业科瑞集团旗下子公司天诚国际投资有限公司达成协议，以11亿欧元收购天诚（德国）医药控股有限公司全部股份。普士高律师事务所、Osborne Clarke为基立福提供法律意见 ；高赢律师事务所则担任天诚德国律师。

基立福成立于1940年，总部位于巴塞罗那，是一家化学及制药公司，主要制造与血清相关产品。2010年，基立福成立中国代表处。此次收购交易完成后，天诚德国所持有的血浆供应商、德国上市公司Biotest 百分之90以上的股份将归基立福所有。

高赢团队由合伙人Gregor Klenk、Carl Bradshaw牵头领导。

Goodwin, Proskauer Rose and Osborne Clarke advise on Grifols’ acquisition of Tiancheng Pharmaceutical Holding

Osborne Clarke and Proskauer Rose have advised Grifols, a Spanish pharmaceutical company, on its $1.3 billion purchase of Tiancheng Pharmaceutical Holding, which was advised by Goodwin Procter.

Established in 1940, the Barcelona-headquartered Grifols is a pharmaceuticals company with focus on blood serum related products. In 2010, Grifols established its China subsidiary. Tiancheng is a German subsidiary of Hong Kong-based Tiancheng International Investment, owning over 90 percent of the shares of Biotest, a listed German healthcare company. Following the transaction, Grifols will replace Tiancheng to become Biotest’s largest shareholder. 

The Goodwin team is led by partners Gregor Klenk and Carl Bradshaw.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.